Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Allianz SE

Allianz SE lessened its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 51.9% in the first quarter, according to its most recent filing with the SEC. The firm owned 65 shares of the biopharmaceutical company’s stock after selling 70 shares during the quarter. Allianz SE’s holdings in Regeneron Pharmaceuticals were worth $41,000 as of its most recent SEC filing.

A number of other institutional investors also recently added to or reduced their stakes in the business. Raiffeisen Bank International AG boosted its position in Regeneron Pharmaceuticals by 302.4% during the 1st quarter. Raiffeisen Bank International AG now owns 20,100 shares of the biopharmaceutical company’s stock worth $12,810,000 after acquiring an additional 15,105 shares during the period. Blair William & Co. IL boosted its position in Regeneron Pharmaceuticals by 2.2% during the 1st quarter. Blair William & Co. IL now owns 1,282 shares of the biopharmaceutical company’s stock worth $813,000 after acquiring an additional 27 shares during the period. Manchester Capital Management LLC boosted its position in Regeneron Pharmaceuticals by 38.5% during the 1st quarter. Manchester Capital Management LLC now owns 223 shares of the biopharmaceutical company’s stock worth $141,000 after acquiring an additional 62 shares during the period. Bank of Nova Scotia boosted its position in Regeneron Pharmaceuticals by 36.0% during the 1st quarter. Bank of Nova Scotia now owns 122,589 shares of the biopharmaceutical company’s stock worth $77,750,000 after acquiring an additional 32,427 shares during the period. Finally, Banco Santander S.A. boosted its position in Regeneron Pharmaceuticals by 58.5% during the 1st quarter. Banco Santander S.A. now owns 11,852 shares of the biopharmaceutical company’s stock worth $7,517,000 after acquiring an additional 4,374 shares during the period. Institutional investors and hedge funds own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN stock opened at $571.54 on Tuesday. The stock’s fifty day simple moving average is $537.72 and its 200-day simple moving average is $601.99. The company has a current ratio of 5.39, a quick ratio of 4.73 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a 1-year low of $476.49 and a 1-year high of $1,211.20. The company has a market capitalization of $61.71 billion, a price-to-earnings ratio of 14.40, a P/E/G ratio of 2.10 and a beta of 0.33.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share for the quarter, topping the consensus estimate of $8.43 by $4.46. The company had revenue of $3,675,600 billion for the quarter, compared to analyst estimates of $3.30 billion. Regeneron Pharmaceuticals had a return on equity of 15.06% and a net margin of 31.37%. The business’s revenue was up 3.6% compared to the same quarter last year. During the same period in the prior year, the firm posted $11.56 EPS. On average, sell-side analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 3rd. Stockholders of record on Monday, August 18th will be issued a dividend of $0.88 per share. The ex-dividend date of this dividend is Monday, August 18th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.6%. Regeneron Pharmaceuticals’s dividend payout ratio is currently 8.87%.

Analyst Ratings Changes

A number of research firms have recently commented on REGN. UBS Group reissued a “neutral” rating on shares of Regeneron Pharmaceuticals in a research note on Friday. Robert W. Baird dropped their price objective on Regeneron Pharmaceuticals from $759.00 to $652.00 and set a “neutral” rating on the stock in a research note on Friday, April 25th. Canaccord Genuity Group reissued a “buy” rating and issued a $850.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Wednesday, July 23rd. Guggenheim boosted their price objective on Regeneron Pharmaceuticals from $810.00 to $815.00 and gave the stock a “buy” rating in a research note on Friday. Finally, Cantor Fitzgerald began coverage on Regeneron Pharmaceuticals in a research note on Tuesday, April 22nd. They issued an “overweight” rating and a $695.00 price objective on the stock. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating, sixteen have given a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, Regeneron Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus target price of $841.30.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.